A combination of omental flap and growth factor therapy induces arteriogenesis and increases myocardial perfusion in chronic myocardial ischemia: Evolving concept of biologic coronary artery bypass grafting  by Takaba, Kiyoaki et al.
A
i
p
c
K
S
Y
Takaba et al Cardiopulmonary Support and Physiologycombination of omental flap and growth factor therapy
nduces arteriogenesis and increases myocardial
erfusion in chronic myocardial ischemia: Evolving
oncept of biologic coronary artery bypass grafting
iyoaki Takaba, MD,a Chunli Jiang, MD,a Shintaro Nemoto, MD, PhD,a Yoshiaki Saji, MD,a Tadashi Ikeda, MD, PhD,a
hinichi Urayama, MS,b Takashi Azuma, BS,c Akishige Hokugo, DDS, PhD,c Sadami Tsutsumi, PhD,casuhiko Tabata, PhD, DMedSc, DPharm,c and Masashi Komeda, MD, PhDa
O
c
m
M
c
F
g
t
t
t
R
w
F
g
l
r
(
·
“
fl
C
a
a
D
a
a
s
H
s
e
CS
PSupplemental material is
available online.
From the Department of Cardiovascular
Surgery,a Human Brain Research Center,b
Kyoto University, Graduate School of
Medicine, Kyoto, Japan, and the Institute
for Frontier Medical Sciences,c Kyoto Uni-
versity, Kyoto, Japan.
This study was supported in part by a grant-
in-aid for scientific research from the Min-
istry of Education, Culture, Sports, Science
and Technology (#17591468), a grant-in-
aid for cardiovascular disease research from
the Japan Heart Foundation/Pfizer Japan
Pharmaceutical, and a grant-in-aid for car-
diac disease research from the Vehicle Rac-
ing Commemorative Foundation.
Read at the Eighty-fifth Annual Meeting of
The American Association for Thoracic
Surgery, San Francisco, Calif, April 10-13,
2005.
Received for publication Dec 22, 2005; re-
visions received June 5, 2006; accepted for
publication June 22, 2006.
Address for reprints: Masashi Komeda,
MD, PhD, Professor and Chairman, Depart-
ment of Cardiovascular Surgery, Graduate
School of Medicine, Kyoto University, 54
Shogoin Kawahara-machi, Sakyo-ku, Kyoto
606-8507, Japan (E-mail: komelab@kuhp.
kyoto-u.ac.jp).
J Thorac Cardiovasc Surg 2006;132:891-9
0022-5223/$32.00
Copyright © 2006 by The American Asso-
ciation for Thoracic Surgeryd
doi:10.1016/j.jtcvs.2006.06.023bjective: The purpose of this study was to evaluate the therapeutic efficacy of the
ombined growth factor therapy with an omental flap in a rabbit model of chronic
yocardial ischemia.
ethods: Chronic ischemia was created in rabbits by placing a constrictor on the left
ircumflex artery. Four weeks later the animals were divided into 3 groups: group
G, in which a gelatin hydrogel sheet incorporating 100 g of basic fibroblast
rowth factor was placed over the left circumflex region followed by covering with
he omental flap including the intact gastroepiploic artery; group F, in which only
he basic fibroblast growth factor sheet was placed; and group N, in which no
reatment was done.
esults: Cine magnetic resonance imaging analysis showed a greater percentage
all thickening in the left circumflex region in group FG than in other groups (group
G, 49.2%  4.5%; group F, 41.2%  3.8%; group N, 32.1%  2.5%, P .035,
roup FG vs group F). A colored microsphere assay showed higher perfusion in the
eft circumflex region in group FG than in group F. Perfusion in the left circumflex
egion was decreased after clamping the gastroepiploic artery pedicle in group FG
before clamping, 2.83  0.72 mL · min1 · g1; after clamping, 1.93  0.59 mL
min1 · g1; P .01). In vivo angiography via gastroepiploic artery showed direct
to-and-fro” visible collaterals between the gastroepiploic and occluded left circum-
ex coronary arteries in group FG.
onclusion: The combined growth factor therapy with an omental flap induced
rteriogenesis and provided additional perfusion via the gastroepiploic artery to
meliorate regional dysfunction in the chronically ischemic myocardium.
espite advances in the treatment for ischemic heart disease, there exist
patients who are not eligible for current revascularization procedures be-
cause of chronic, diffuse, and poorly graftable coronary lesions.1
As progress has been made in the basic studies on growth factors in the normal
ngiogenic process, the concept of therapeutic angiogenesis was developed as an
lternative treatment for these patients over the past 2 decades.2 Preclinical animal
tudies with various growth factor delivery strategies have shown promising data.3,4
owever, recent randomized double-blind clinical trials showed disappointing re-
ults with respect to therapeutic efficacy.5,6
Historically, before the advancement of cardiopulmonary bypass, the concept of
mploying an omental flap to provide revascularization for the ischemic myocar-
ium was attempted in patients with ischemic heart disease. However, the thera-
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CSPeutic efficacy of omentopexy was not so efficient for rapid
ecovery. There exist the clinical limitations with the ther-
peutic efficacy of ometopexy as well as with that of growth
actor therapy.7
To offer a more effective therapeutic option for these
atients, we developed a combined method involving an
mental flap and growth factor as a new alternative surgical
ethod. We called this strategy “biologic coronary artery
ypass grafting.” Our previous study demonstrated that the
ethod augmented the therapeutic efficacy of growth factor
herapy using sustained-release basic fibroblast growth fac-
or (bFGF) by applying a pedicled omental flap in a rabbit
odel of acute myocardial infarction, whereas omentopexy
lone was not so effective as growth factor therapy.8 Re-
arding the clinical application, the purpose of the present
tudy was to evaluate its therapeutic efficacy and to verify
ts superior therapeutic effect over growth factor therapy in
he chronically ischemic myocardium.
aterials and Methods
xperimental Animals and Study Protocol
orty adult male white Japanese rabbits (weighing 3.5-4.0 kg)
Shizuoka Laboratory Animal Center, Shizuoka, Japan) were used
n this study. All the animal experiments in this study were
erformed according to the institutional guidelines on animal
xperimentation of Kyoto University, which conform to the “Guid-
nce for the Care and Use of Laboratory Animals” law in Japan.
Each animal received two consecutive operations during the
tudy. In the first operation, we created chronic myocardial isch-
mia by placing an ameroid constrictor. Four weeks after the first
peration, animals were assigned into 3 groups as follows: group
(n  8) received no additional treatment after creation of the
yocardial ischemia; in group F (n  8) a gelatin hydrogel sheet
ncorporating 100 g of bFGF was placed over the epicardium of
he ischemic area; and in group FG (n  8) a gelatin hydrogel
heet incorporating 100 g of bFGF was placed over the ischemic
rea, followed by covering with an omental flap. Four weeks
fter the second operation, animals were put to death with an
verdose of pentobarbital to harvest the cardiac tissue for
urther assessments.
Anesthetic protocol for the surgical procedures and func-
ional measurements. All surgical procedures in this study were
Abbreviations and Acronyms
bFGF  basic fibroblast growth factor
FS  fractional shortening
GEA  gastroepiploic artery
LCx  left circumflex coronary artery
LV  left ventricular
LVEDD left ventricular end-diastolic dimension
LVEF  left ventricular ejection fraction
LVESD  left ventricular end-systolic dimension
MRI magnetic resonance imagingerformed with the animals under general anesthesia as described 1
92 The Journal of Thoracic and Cardiovascular Surgery ● Octoelow. The rabbits were sedated with an intravenous injection of
odium pentobarbital (30 mg/kg) and then intubated with an end-
racheal tube (4.0-mm inner diameter, neonatal end-tracheal tube;
allinckrodt Medical, St Louis, Mo) for mechanical ventilation
tidal volume of 10-15 mL and a minute ventilation rate of 40-60
reaths/min) (7025 Rodent Ventilator; Ugo Basile, Rome, Italy).
eneral anesthesia was maintained with 1.0% to 2.0% of isoflu-
ane mixed with room air. Rectal temperature was maintained at
8°C-39°C with a heat pad during the surgical procedures.
reation of Chronic Myocardial Ischemia With
n Ameroid Constrictor: The First Operation
e used a rabbit model of chronic myocardial ischemia according
o the method previously described by Operschall and coworkers.9
n brief, a left thoracotomy was performed at the fourth intercostal
pace in a sterile manner. After the pericardium was opened, the
ain branch of the left circumflex (LCx) coronary artery was identi-
ed. We applied a commercially available hygroscopic ameroid con-
trictor specially designed for constricting rabbit coronary arteries
5-mm diameter, 1.5-mm height: Research Instruments SW, San
iego, Calif). We fixed it on the epicardial surface of the heart,
urrounding the targeted coronary artery, with a 6-0 polypropylene
uture placed around its circumference. The knot was softly tied to
lace the ameroid constrictor on the epicardial surface of the
argeted artery preventing complete occlusion of the flow, as
emonstrated by both electrocardiographic changes and visual
lanching of the myocardium. Careful inspection was maintained
or 10 minutes after placement of the constrictor. The thoracotomy
as closed in layers, and residual air in the thoracic cavity was
vacuated.
Echocardiographic measurements of time-course cardiac
unction. Left ventricular (LV) function was assessed by trans-
horacic echocardiography at each procedure (every 4 weeks)
nder general anesthesia as described above. A commercially
vailable echocardiograph with a 7.5-MHz pediatric transducer
Vivid 7; GE Medical, Tokyo, Japan) was used for all studies to
btain serial images through a left parasternal approach. LV end-
iastolic and end-systolic dimensions (LVEDD and LVESD, re-
pectively) were measured with M-mode tracings from the short-
xis view at the papillary muscle level. Fractional shorting (FS)
as calculated from these data as follows: FS (%)  (LVEDD –
VESD)/(LVEDD)  100. The data were averaged over 3 con-
ecutive cardiac cycles. Another observer who was blinded to the
reatment groups performed all measurements.
Preparation of the gelatin hydrogel sheet incorporating
FGF. Gelatin hydrogel sheets (Nitta Gelatin Co, Osaka, Japan)
ere prepared as described previously.10 In brief, the sheets were
reeze-dried and trimmed in 5  5–mm squares and 0.7-mm thick,
hen impregnated with an aqueous solution containing 100 g of
uman recombinant bFGF (Kaken Pharmaceutical Co, Tokyo,
apan). All the processes were conducted under sterile conditions.
reatment: The Second Operation
our weeks after the first operation, each animal in groups FG and F
eceived 2 different types of treatment as the second operation. We
xcluded rabbits if they showed an FS more than 30% or less than
5% in the echocardiograhic assessment before the second operation.
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PIn group F, a median sternotomy was performed to place the
FGF-incorporated hydrogel sheet (bFGF sheet) on the epicardium
f the ischemic area (LCx region) by stitching around the edge of
he sheet. In group FG, a small upper midline laparotomy and
edian sternotomy were performed to take the omentum out from
he peritoneal space into the mediastinal space, preserving the arch
tructure of the left gastroepiploic artery (GEA). We created the
ole at the diaphragm and passed the omental flap through the hole
nto the pericardial cavity. The bFGF sheet was placed on the
picardium of the ischemic area, followed by covering the sheet
ith the harvested omental flap.
agnetic Resonance Imaging Analysis of Cardiac
erformance
our weeks after the second operation, we performed electrocar-
iographically gated cine magnetic resonance imaging (MRI)
cans (Siemens Sonata 1.5 Tesla; Siemens Medical System, Er-
angen, Germany) while the animals were anesthetized with an
ntravenous injection of sodium pentobarbital (30 mg/kg). A cir-
ular polarized extremity coil was wrapped around the chest for
ignal acquisition. Six sequential images of LV short-axis views
very 2.5 mm were obtained to cover the entire LV volume from
he base to the apex over 10 heartbeats. Custom designed software
Image J 1.3 version; Scion Corporation, Frederick, Md) was used
o define myocardial borders and measure the wall thickness in the
Cx region by the modified centerline method.11 The circumfer-
ntial lengths at end-diastole and end-systole at the papillary
uscle level were measured. LV volumes at end-systolic and
nd-diastolic phase (LVESV and LVEDV, respectively) were
omputed by the area-length method and used to calculate the LV
jection fraction (LVEF) as follows: LVEF (%)  (LVEDV –
VESV)/LVEDV  100.12
easurement of Regional Myocardial Blood Flow
our weeks after the second operation, we evaluated regional
yocardial blood flow in the ischemic area (LCx region) with a
olored microsphere technique (DYE-TRCK; Triton Technology,
oronto, Ontario, Canada). A repeated left thoracotomy was per-
ormed to expose the left atrial appendage. After systemic hepa-
inization (1000 IU heparin), 1.2 million red colored microspheres
15 m in diameter) were injected into the left atrium for more
han 30 seconds while reference blood samples were drawn from
he descending aorta at a rate of 1.0 mL/min for 90 seconds. In
roup FG, 1.2 million yellow colored microspheres were consec-
tively injected to evaluate the GEA flow into the ischemic area in
he same manner after clamping the GEA pedicle at the level of the
iaphragm through a small laparotomy. After euthanasia with an
verdose of pentobarbital, the LV was isolated and 3 short-axis
ransverse slices were cut out, while the transverse slices at the
idventricular level were cut into 4 radial segments. According to
he manufacturer’s protocol, we extracted microspheres by potas-
ium hydroxide digestion from the lateral midventricular segments
nd blood samples. The dyes were extracted from the spheres with
00 L of dimethylformamide, and their concentrations were
etermined by spectrophotometry (UV-mini 1240; Shimazu. Co,
yoto, Japan). The myocardial blood flow (Qs) was calculated as
ollows: Qs (mL · min1 · g1)  (As/Ar) Qr (mL/min)/Wt (g),
here Qr represents with the withdrawal rate of the reference a
The Journal of Thoraciclood, As and Ar represent the absorbance in the sample tissue and
eference blood, and Wt represents the tissue weight.
istologic Analysis
our weeks after the second operation, another series of 6 rabbits
n each group was used for histologic analysis. After euthanasia,
he heart was perfused at 100 mm Hg for 10 minutes with 10%
ormalin and then immersion-fixed in 4% formalin. We isolated
he LV and cut out the short-axis transverse slice corresponding to
he ischemic region situated 2 mm below the implanted ameroid
onstrictor. This transverse slice of LV at the papillary muscle
evel was embedded in paraffin and sectioned at 4-m thickness.
he primary mouse monoclonal antibody against –smooth mus-
le actin (clone 1A4; Sigma Chemical Co, St Louis, Mo) was
ncubated with the tissue section, followed by incubation with a
iotin-rabbit anti-mouse immunoglobulin G. Tetramethylrhodam-
ne isothiocyanate–conjugated secondary antibody was used to
etect expression of –smooth muscle actin. The tissue sections
ere counterstained with hematoxylin and eosin. The numbers of
rterioles were counted under a microscopic field (100) to deter-
ine the arteriolar density. Five high-power fields were randomly
elected for the vessel counts at the center of the lateral myocardial
erritories in each section. An arteriole was defined as a vessel in
iameter more than 50m. Quantification was performed in a blinded
anner with a minimum of 3 sections for each animal.
icrovascular Corrosion Cast
e made a microvascular corrosion cast to evaluate 3-dimensional
ollateral development in group FG, as previously described.13
our weeks after the second operation, the resin (Mercox CL;
ainippon Ink Chemical, Tokyo, Japan) was injected antegradely
nto the celiac arterial trunk and retrogradely into the descending
horacic aorta after systemic heparinization (1000 IU heparin). The
hole body was immersed in hot water for a few hours to solidify
he resin in the blood vessels. The heart covered with the omental
ap was carefully harvested and then placed into 10% sodium
hlorate solution to corrode the residual adjacent tissue except for
he arteries. This specimen was fixed with liquid nitrogen. After
eing coated with platinum-palladium, an image of collateral vessels
as obtained by scanning electron microscopy (S4000; Hitachi Co,
okyo, Japan).
n Vivo Angiography
different series of 5 rabbits in group FG were anesthetized as
escribed above. The right common carotid artery was cannulated
ith a 4F sheath introducer system (Goodtech; Goodman Co,
agoya, Japan) after systemic heparinization (1000 IU heparin). A
.2F catheter (Selecon PA catheter; Clinical Supply Co, Gifu, Japan)
as selectively inserted into the celiac arterial trunk under fluoros-
opy (OEC9800; GE Medical, Tokyo, Japan). The serial images of
he collateral arteries were recorded at the rate of 30 frames per
econd with manual injection of 10 to 30 mL of diluted nonionic
ontrast medium (Iopamiron 300; Schering Co, Munich, Germany).
ollateralization and myocardial blush were assessed qualitatively.
tatistical Analysis
ll the data are shown as mean  standard deviation. Statisticalnalyses were performed with the Stat-View software (SAS Insti-
and Cardiovascular Surgery ● Volume 132, Number 4 893
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CSPute Inc, Cary, NC). Comparisons of echocardiographic data
mong the groups were performed by 2-way repeated measures
nalysis of variance. Comparisons of other data among the groups
ere performed by 1-way analysis of variance. If significance was
ound for a group, a time effect, or a group-by-time interaction,
ifferences between groups were specified with the Tukey-Kramer
est for post hoc comparisons.
esults
easibility
here was no periprocedural mortality. Two rabbits in
roup N died at 5 weeks after the first operation with
vidence of lateral myocardial infarction at autopsy.
ime-course Changes of Global LV Function Assessed
y Serial Transthoracic Echocardiography
our weeks after the constrictor implantation, FS was sig-
ificantly reduced in all groups. Four weeks after each
reatment, group FG showed a greater FS increase than
roup F (P  .038 vs group F) (Figure 1, A). Four weeks
fter the constrictor implantation, LVEDD was increased in all
roups. Four weeks after each treatment, group FG and group
showed a greater recovery in LVEDD than group N, but
here was no significant difference between group FG and F
P  .143 vs group F, P  .008 vs group N) (Figure 1, B).
ssessment of Regional and Global LV Function
y Cine MRI
our weeks after each treatment, percentage wall thickening
n the LCx region was significantly higher in group FG than
n groups F and N (P  .035 vs group F) (Figure 2, B).
lthough there was no significant difference in the circum-
erential length at end-diastole between groups F and FG,
ircumferential length at end-systole was significantly well
aintained in group FG compared with group F. LVEF was
ignificantly higher in group FG than in group F (Table E1).
ssessment of Regional Myocardial Blood Flow
n the Ischemic Region Using the Colored
icrosphere Technique
our weeks after each treatment, regional myocardial blood
ow in the LCx region was significantly higher in group FG
han in group F (P  .035 vs group F) (Figure 3, A). In
roup FG, the regional myocardial blood flow in the LCx
egion was significantly decreased after the GEA pedicle
as clamped (P  .008) (Figure 3, B).
mmunnohistochemical Analysis of Neoarterial
ormation in the Ischemic Region
significantly greater number of arterioles in the LCx
egion were identified in group FG than in group F (P 
048 vs group F) (Figure 4, B). 
94 The Journal of Thoracic and Cardiovascular Surgery ● Octohree-Dimensional Assessment of Collateral Vessels
y Scanning Electron Microscopy in the
icrovascular Corrosion Cast Specimen
he corrosion cast specimen from group FG showed marked
ollateral formation between the GEA and native coronary
rterial branches (Figure 5, A). The macroscopically visible
ollateral vessels were easily identified (Figure 5, B). Further-
ore, scanning electron microscopic analysis disclosed that
he diameter of these collateral arteries was more than 150
igure 1. Time course changes of global LV function assessed by
chocardiography. FS (A) and LVEDD (B) assessed before place-
ent of a constrictor (baseline: 0 week) and at treatment
4 weeks) and 4 weeks after treatment (8 weeks). Asterisk indi-
ates P < .01 versus group N; dagger indicates P < .05 versus
roup F. N.S, Not significant.m (Figure 5, C ).
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Pngiographic Assessment of the Collateral
ommunication Between the GEA and the Native
ccluded LCx Artery
n group FG, communication between the GEA and native
oronary arterial branches was identified in all animals. We
ound direct “to-and-fro” communications between the GEA
nd the proximally occluded LCx artery in 3 animals (see
ideo). In another 2 animals, direct opacification of the prox-
igure 2. Regional LV function in the ischemic region assessed
y cine MRI. A, Representative cine MRI images of a short-axis
iew at the papillary muscle level in group FG at 4 weeks after
reatment. Regional myocardial thickening assessed by the mod-
fied centerline method; changes in length of cords between
nd-diastole and end-systole determine wall thickening. RV,
ight ventricular cavity; LV, left ventricular cavity; Cx, circumflex
rtery. B, Percent wall thickening in the ischemic region as-
essed by cine MRI analysis at 4 weeks after treatment in each
roup. Asterisk indicates P < .01 versus group N; dagger indi-
ates P < .05 versus group F.mally occluded LCx artery was not demonstrated, but delayed o
The Journal of Thoracicpacification through the marked collaterals from the GEA
as easily identified.
iscussion
n the present study, we demonstrated the therapeutic effects
f the combined method involving an omental flap includ-
ng the GEA and single growth factor therapy using a bFGF
ustained-releasing biodegradable sheet. The method devel-
igure 3. Regional myocardial blood flow (rMBF) in the LCx
egion assessed by the colored microsphere technique. A, rMBF
n LCx region at 4 weeks after each treatment assessed by
olored microsphere technique. Asterisk indicates P< .01 versus
roup N; dagger indicates P < .05 versus group F. B, The change
f rMBF in the LCx region in group FG before and after clamping
he GEA pedicle. Asterisk indicates P < .01. ANOVA, Analysis of
ariance.ped collateral vessels directly from the GEA and provided
and Cardiovascular Surgery ● Volume 132, Number 4 895
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CSPdditional perfusion via the GEA to improve regional LV
ysfunction resulting from chronic ischemia. Furthermore,
he combined method showed its superior therapeutic effect
ver single growth factor therapy in the chronically isch-
mic myocardium.
The microsphere assay in the present study showed that
he combined method provided more perfusion in the isch-
mic region than single growth factor therapy. Moreover, in
he group treated by the combined method, we observed
2% reduction of the perfusion in the ischemic region after
lamping the GEA. These results clearly demonstrated that
he combined method provided additional perfusion to the
schemic region via the GEA. In the cine MRI analysis, the
ombined method showed a marked improvement in re-
ional contractility in the ischemic region as expressed in
ercentage wall thickening, which is referred to as an index
f mechanical function across all layers of the myocardium.
enerally, providing adequate perfusion to all myocardial
ayers in the ischemic region is needed to improve regional
ysfunction caused by ischemia.14 These findings demon-
trated that the combined method can provide additional
lood flow through the GEA to perfuse all myocardial
ayers of the region of chronic ischemia.
Perfusion reflects the result of successful collateral for-
ation. The development of effective collateral vessels
nvolves arteriogenesis, which is referred to as a process
ased on growth and remodeling into functional vessels.15
rteriogenesis is considered to be more important than
ngiogenesis due to higher perfusion capacity.16 As the
orphologic parameter for arteriogenesis, the immunohis-
ologic analysis in the present study showed that the com-
ined method developed more arterioles in the ischemic
egion compared with single growth factor therapy. In ad-
ition, the combined method developed sizable collateral
essels directly from the GEA, as shown in the vascular
orrosion cast study. These results suggest that the com-
ined method induced arteriogenesis to develop the collat-
ral vessels directly from the GEA in the chronically isch-
mic myocardium.
As described in our previous study, our strategy for
eveloping effective collaterals for advanced coronary le-
ions is to apply an omental flap involving the GEA as
ondiseased donor artery with high perfusion capacity.8 The
rocess of arteriogenesis is mediated via shear stress.15 The
ntracoronary collaterals induced by single growth factor
herapy provide the inadequate limited flow through the
bstructed native donor coronary arteries to induce arterio-
enesis for developing effective collateral vessels.17 In con-
rast, an omental flap can provide the adequate additional
ow via the GEA as an unobstructed donor artery. From
hese considerations, the GEA involved in an omental flap
an play an important role as an independent, unobstructed
xtracardiac blood source to provide additional collateral y
96 The Journal of Thoracic and Cardiovascular Surgery ● Octoow (shear stress) for enhancing arteriogenic activity in the
hronically ischemic region.
Conversely, from the results of our studies, it is reason-
ble to conjecture that the combined method may enhance
he angiogenic efficacy of omentopexy by interposing the
FGF sheet. As demonstrated by our previous study, the
herapeutic efficacy of omentopexy alone was inferior to
hat of single growth factor therapy with bFGF sheet.8 Five
ecades ago, omentopexy was used to create collaterals
rom the GEA. However, in some cases, it took several
igure 4. Histologic assessment of arteriogenesis in the ischemic
yocardium after treatment. A, Representative images of immu-
ohistochemical staining in group F and group FG. Arterioles in
he LCx region were stained with -smooth muscle actin anti-
ody. Arrows indicate arterioles with a diameter more than 50
m. Scale bar indicates 100 m in length (original magnification
100). B, Quantification of the number of arterioles with a diam-
ter more than 50 m in each group. Asterisk indicates P < .01
ersus group N; dagger indicates P< .05 versus group F. ANOVA,
nalysis of variance.ears to develop effective ones.18 These facts suggest that
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Phe clinical disadvantage of omentopexy is its therapeutic
nefficiency. The interposed bFGF sheet possibly en-
ances the angiogenic effects of the superimposed omen-
al flap in the combined method. It can accelerate the
ormation of collaterals between native coronary arteries
nd omental tissue to achieve the vessel connections
irectly from the GEA.
Omental flap itself has been an attractive tissue for car-
iothoracic surgeons to stimulate revascularization of isch-
mic tissue.19 Recent basic studies have elucidated the
echanism of the angiogenic action induced by omental
issue. The adipocytes in the omental tissue release a num-
er of angiogenic growth factors, such as vascular endothe-
Figure 5. Microvascular corosion cast image of col
Representative image of a microvascular corosion cast
(original magnification 6). Cx, Left circumflex arter
collateral formation between distally occluded LCx
magnification60). C, Scanning electron micrographs o
microvascular corrosion cast specimens.ial growth factor and bFGF. This fact suggests that an m
The Journal of Thoracicmental flap can act as a physiologic exogenous source of
ultiangiogenic factors that are synergistically involved in
he process of arteriogenesis.20,21 Moreover, the interposed
FGF sheet possibly can augment the expression of other
rowth factors in the omental tissue.22 However, further
nvestigation is needed to clarify the participation of the
dditive growth factors released from the omental tissue in
he process of collateral formation from the GEA in the
ombined method.
Other experimental studies were reported to enhance the
ffects of omentopexy. Ruel and associates23 demonstrated
he excellent angiogenic effect of a gastric submucosal
atch as an endogenous source of growth factors in a swine
al formation in group FG. A, The whole specimen.
imen in group FG. Scale bar indicates 10 mm in length
A, gastroepiploic artery. B, Representative image of
GEA. Scale bar indicates 1 mm in length. (Original
laterals between distally occluded LCx and GEA in thelater
spec
y; GE
and
f colodel of chronic myocardial ischemia. Kanamori and col-
and Cardiovascular Surgery ● Volume 132, Number 4 897
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CSPeagues24 showed that omentopexy enhanced the angiogenic
ffect of cell therapy in a swine model of acute myocardial
nfarction. Compared with these studies, the combined method
n the present study is safer and less invasive because it does
ot need a gastrectomy or bone marrow aspiration.
Several limitations of this study must be addressed. First,
e did not quantitatively evaluate the functional capacity of
eveloped collaterals in this study. However, the identifica-
ion of angiographically visible “to-and-fro” collaterals can
e considered as the qualitative evidence of functional
ollateral formation. Second, there existed a variation in
he myocardial ischemia in the animal model of chronic
schemia with an Ameroid constrictor, although we de-
igned the study to minimize this variation. As a further
tudy, the efficacy of the method must be evaluated in
yperlipidemic or diabetic animal models because endo-
helial dysfunction resulting from these pathologic fac-
ors is one of the most important obstacles to achieving
linical therapeutic angiogenesis.25,26
In conclusion, we demonstrated that the combined method
eveloped sizable collateral vessels directly from the GEA to
meliorate regional myocardial dysfunction in the chroni-
ally ischemic myocardium. We verified that the effect of
he present method is superior to that of single angiogenic
rotein therapy. The present method may improve the clin-
cal limitations in therapeutic angiogenesis and expand the
urgical indication for patients with severe coronary artery
isease.
We thank Toshiya Sato, MD, PhD, for the instructions of
tatistical analysis, Shinji Tomita, MD, PhD, for the reviewing our
anuscript, and Mrs Fumiyo Kataoka for her assistance in histo-
ogic assessment.
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iscussion
r Todd K. Rosengart (Evanston, Ill). In this study the authors
ave convincingly demonstrated physiologically relevant increases
n blood flow using an omental flap containing the GEA supple-
ented by bFGF application in the area of the omental flap. This
ork extends an increasing line of research looking at arteriogen-
ber 2006
eg
i
o
h
t
t
a
f
a
o
v
t
C
e
d
w
s
g
m
p
d
b
f
w
t
w
y
Takaba et al Cardiopulmonary Support and Physiologysis, as opposed to angiogenic techniques, which we’re actually
oing to talk about in a minute.
I have 3 questions for you.
It is widely known that Vineberg-type procedures, be with it the
nternal thoracic artery, as has been described for several decades,
r as now described, will increase myocardial blood flow. Do you
ave any data with the GEA control, that is, without using bFGF,
o describe the relative contribution of the GEA alone as opposed
o your bFGF angiogenic or arteriogenic therapies?
Second, we have previously demonstrated that the omentum is
n extremely rich supply of vascular endothelial growth factor; in
act, it is the highest concentrations in the body. This presumably
ccounts for its role in abdominal healing, for example, and the use
f omental flaps in general. Do you have any data looking at
ascular endothelial growth factor alone as opposed to the omen-
um as your angiogenic/arteriogenic supplement?
Finally, similar work in this regard has been performed by
ohn and his associates, and has been reported previously, usingThe Journal of Thoracicure. Do you have any information or are you aware of Dr Cohn’s
ork compared with your own? Potentially that would provide
ome insights into the relative contribution of the GEA.
Dr Takaba. To answer your first question, we have investi-
ated just omentopexy alone in a previous study of an acute
yocardial infarction model. However, the effect of just omento-
exy was lower than angiogenic factor alone. So now we can
emonstrate just omentopexy.
Concerning your second question, basically we investigated
FGF, and bFGF is investigated for the effect of this. We have data
or this.
Please repeat the third question.
Dr Rosengart. Are you familiar with Dr Cohn’s prior work
ith a similar model in this area?
Dr Sellke. He used a gastric patch, based on the GEA, and did
he same thing without the growth factor, but he found that there
as increased perfusion in the chronically ischemic territory. Are
ou familiar with that?CS
Pssentially a very similar model, GEA as a Vineberg-type proce- Dr Takaba. I am not. Sorry.and Cardiovascular Surgery ● Volume 132, Number 4 899
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EF, ejection fraction. *P  .01 versus group N. †P  .01 versus group F.
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CSPABLE E1. Cine MRI analysis of global LV function
Group FG Group F Group N
ircumferential length at
end-diastole (mm)
45.3 3.1* 44.4 2.8* 54.4 4.8
ircumferential length at
end-systole (mm)
30.3 3.8*† 37.5 2.1* 43.4 2.5
VEDV (mm3) 3410 345* 3253 411* 4354 508
VESV (mm3) 1398 257*† 2182 280* 3125 487
F (%) 56.0 8.8*† 30.8 7.8* 25.5 6.8
RI, Magnetic resonance imaging; LV, left ventricular; LVEDV, left ven-
ricular end-diastolic volume; LVESV, left ventricular end-systolic volume;ctober 2006
